GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

Paola Sette, Nduka Amankulor, Aofei Li, Marco Marzulli, Daniela Leronni, Mingdi Zhang, William F. Goins, Balveen Kaur, Chelsea Bolyard, Timothy P. Cripe, Jianhua Yu, E. Antonio Chiocca, Joseph C. Glorioso, Paola Grandi

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


The use of mutant strains of oncolytic herpes simplex virus (oHSV) in early-phase human clinical trials for the treatment of glioblastoma multiforme (GBM) has proven safe, but limited efficacy suggests that more potent vector designs are required for effective GBM therapy. Inadequate vector performance may derive from poor intratumoral vector replication and limited spread to uninfected cells. Vector replication may be impaired by mutagenesis strategies to achieve vector safety, and intratumoral virus spread may be hampered by vector entrapment in the tumor-specific extracellular matrix (ECM) that in GBM is composed primarily of type IV collagen. In this report, we armed our previously described epidermal growth factor receptor (EGFR)vIII-targeted, neuronal microRNA-sensitive oHSV with a matrix metalloproteinase (MMP9) to improve intratumoral vector distribution. We show that vector-expressed MMP9 enhanced therapeutic efficacy and long-term animal survival in a GBM xenograft model.

Original languageEnglish (US)
Pages (from-to)214-222
Number of pages9
JournalMolecular Therapy - Oncolytics
StatePublished - Dec 20 2019
Externally publishedYes


  • Glioblastoma multiforme = GBM
  • OVs derived from herpes simplex virus = oHSV
  • Oncolytic vectors = OVs
  • extracellular matrix = ECM
  • matrix metalloproteinase 9 = MMP9

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival'. Together they form a unique fingerprint.

Cite this